Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase‐2 and MMP‐9

The transcription factor avian erythroblastosis virus E26 (V‐Ets) oncogene homolog 1 (Ets‐1) is involved in tumor development and progression through the transcriptional regulation of several matrix‐degrading enzyme systems, including matrix metalloproteinases (MMPs). It has been demonstrated that the MMPs are expressed strongly in high‐grade meningiomas. To determine the biologic significance of Ets‐1 in the progression of benign meningiomas, the authors investigated the expressions of Ets‐1 and its target genes MMP‐2 and MMP‐9 in primary and recurrent, Grade 1 meningiomas.

[1]  F. Soncin,et al.  Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth , 2005, Oncogene.

[2]  D. Figarella-Branger,et al.  Lack of alkaline phosphatase activity predicts meningioma recurrence. , 2005, American journal of clinical pathology.

[3]  T. Pietsch,et al.  Inactivation of Ets 1 transcription factor by a specific decoy strategy reduces rat C6 glioma cell proliferation and mmp-9 expression. , 2005, International journal of molecular medicine.

[4]  A. Nerlich,et al.  Enhanced expression and activation of major matrix metalloproteinases in distinct topographic areas of invasive breast carcinomas. , 2005, International journal of oncology.

[5]  A. Friedman,et al.  Surgical Management of Petroclival Meningiomas: Defining Resection Goals Based on Risk of Neurological Morbidity and Tumor Recurrence Rates in 137 Patients , 2005, Neurosurgery.

[6]  L. de Ridder,et al.  The hTERT‐protein and Ki‐67 labelling index in recurrent and non‐recurrent meningiomas , 2005, Cell proliferation.

[7]  A. Deimling,et al.  The transcription factor Ets-1 is expressed in human amniochorionic membranes and is up-regulated in term and preterm premature rupture of membranes , 2005, Journal of perinatal medicine.

[8]  O. Arrieta,et al.  Coexpression of hepatocyte growth factor/scatter factor (HGF/SF) and its receptor cMET predict recurrence of meningiomas. , 2004, Cancer letters.

[9]  C. López-Otín,et al.  Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. , 2004, The International journal of developmental biology.

[10]  Chae-Yong Kim,et al.  Correlation of Clinical and Biological Parameters with Peritumoral Edema in Meningioma , 2002, Journal of Neuro-Oncology.

[11]  R. Alday,et al.  Meningiomas of the basal posterior fossa. Surgical experience in 80 cases. , 2004, Neurocirugia.

[12]  K. Kunishio,et al.  Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 Expressions Correlate with the Recurrence of Intracranial Meningiomas , 2004, Journal of Neuro-Oncology.

[13]  T. Turpeenniemi‐Hujanen,et al.  Matrix Metalloproteinase 2 (MMP-2) Immunoreactive Protein is Associated with Poor Grade and Survival in Brain Neoplasms , 2004, Journal of Neuro-Oncology.

[14]  R. Béliveau,et al.  Expression of matrix metalloproteinases and their inhibitors in human brain tumors , 2004, Clinical & Experimental Metastasis.

[15]  A. Das,et al.  Expression of extracellular matrix markers in benign meningiomas , 2003, Neuropathology : official journal of the Japanese Society of Neuropathology.

[16]  C. Thorns,et al.  Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. , 2003, Anticancer research.

[17]  Jürgen Dittmer,et al.  The Biology of the Ets1 Proto-Oncogene , 2003, Molecular Cancer.

[18]  Hiroyuki Yamamoto,et al.  Association of ets‐related transcriptional factor E1AF expression with tumour progression and overexpression of MMP‐1 and matrilysin in human colorectal cancer , 2003, The Journal of pathology.

[19]  Ivan Stamenkovic,et al.  Extracellular matrix remodelling: the role of matrix metalloproteinases , 2003, The Journal of pathology.

[20]  Takahiro Sato,et al.  Ets‐1 and integrin beta3 for lung metastasis from colorectal cancer , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[21]  J. Mosnier,et al.  Stromelysin‐3 is expressed by aggressive meningiomas , 2002, Cancer.

[22]  H. Sasaki,et al.  Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. , 2001, The Journal of surgical research.

[23]  J. Nesland,et al.  Ets-1 mRNA Expression in Effusions of Serous Ovarian Carcinoma Patients Is a Marker of Poor Outcome , 2001, The American journal of surgical pathology.

[24]  T. Mathiesen,et al.  Expression of matrix metalloproteinases 2 and 9 in meningiomas associated with different degrees of brain invasiveness and edema. , 2001, Journal of neurosurgery.

[25]  A. Sharrocks.  The ETS-domain transcription factor family , 2001, Nature Reviews Molecular Cell Biology.

[26]  H. Kamitani,et al.  Recurrence of convexity meningiomas: tumor cells in the arachnoid membrane. , 2001, Surgical neurology.

[27]  A. Wellmann,et al.  Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression. , 2001, International journal of molecular medicine.

[28]  A. Wellmann,et al.  The Ets‐1 transcription factor is up‐regulated together with MMP 1 and MMP 9 in the stroma of pre‐invasive breast cancer , 2001, The Journal of pathology.

[29]  T. Nakayama,et al.  Expression of the ets-1 Proto-Oncogene in Human Colorectal Carcinoma , 2001, Modern Pathology.

[30]  H. Drobecq,et al.  Expression and purification of recombinant mouse Ets-1 transcription factor. , 2001, Protein expression and purification.

[31]  M. Trojanowska.  Ets factors and regulation of the extracellular matrix , 2000, Oncogene.

[32]  V. Sementchenko,et al.  Ets target genes: past, present and future , 2000, Oncogene.

[33]  S. Nakamura,et al.  Immunohistochemical expression of Ets‐1 transcription factor and the urokinase‐type plasminogen activator is correlated with the malignant and invasive potential in meningiomas , 2000, Cancer.

[34]  Kyosuke Yamamoto,et al.  Involvement of the Ets-1 gene in overexpression of matrilysin in human hepatocellular carcinoma. , 2000, Cancer research.

[35]  H. Saeki,et al.  Expression of Ets‐1 transcription factor is correlated with penetrating tumor progression in patients with squamous cell carcinoma of the esophagus , 2000, Cancer.

[36]  S. Paek,et al.  Long-term outcome and growth rate of subtotally resected petroclival meningiomas: experience with 38 cases. , 2000, Neurosurgery.

[37]  R. Prayson,et al.  Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas. , 1999, Archives of pathology & laboratory medicine.

[38]  R. Alday,et al.  Risk Factors Predicting Recurrence in Patients Operated on for Intracranial Meningioma. A Multivariate Analysis , 1999, Acta Neurochirurgica.

[39]  R. Mccomb,et al.  Pathology and Genetics of Tumours of the Nervous System , 1998 .

[40]  W. Couldwell,et al.  Petroclival meningiomas: surgical experience in 109 cases. , 1996, Journal of neurosurgery.

[41]  Y. Okada,et al.  A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[42]  U. Moll,et al.  Inhibition of matrix metalloproteinase 9 activation by a specific monoclonal antibody. , 1993, Hybridoma.

[43]  M Schemper,et al.  Estrogen receptor analysis on biopsies and fine-needle aspirates from human breast carcinoma. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1986, The American journal of pathology.